DNDi is pleased to announce a new partnership with Takeda Pharmaceutical Company Limited whose multi-year commitment was made through Takeda employees’ voting for Global Corporate Social Responsibility (CSR) Program 2019.
by Sunyoto T, Potet J, den Boer M, Ritmeijer K, Postigo JAR, Ravinetto R, Alves F, Picado A, Boelaert M.
BMJ Open, May 2019
9-10 May 2019
London, UK
Paris/Geneva – 30 January 2019
Marketing authorization of fexinidazole for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis, more commonly known as sleeping sickness, has been granted in the Democratic Republic of Congo (DRC). This approval paves the way for the distribution of fexinidazole in endemic countries this year, with another submission planned in Uganda.
19 February 2019
Paris, France
October 2018
To help inform the Canadian government’s approach to biomedical innovation, particularly as relates to innovations of public health importance, DNDi has submitted a contribution providing concrete evidence of DNDi’s experience implementing needs-driven, open, collaborative R&D. The contribution recommends a series of progressive policy steps Canada can support to re-orient the global biomedical R&D system so that it (1) prioritizes patient and public health needs; (2) is sustainably financed; and (3) incorporates global norms that will enable the discovery, development, and delivery of and equitable access to innovations of public health importance.